Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Findings from a recent study suggest that the presence of negative myoclonus may serve as a diagnostic clue for progressive myoclonus ataxia, suggesting the presence of genetic disorders.

Negative Myoclonus Associated With Severe Motor Implications in Progressive Myoclonus Ataxia

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

Understanding the Root of REM Behavior Disorder and Other Parasomnias

Videos

The neurologist at Mass General Hospital discussed adopting AI technologies in neurology practice, emphasizing the importance of addressing equity concerns alongside technological advancements. [WATCH TIME: 5 minutes]

Navigating Challenges and Opportunities With AI Adoption in Neurological Practice: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

Subgroup analyses support PrimeC’s potential in ALS treatment, aiming to inform upcoming trials for efficacy.

ALS Candidate PrimeC Shows Greater Treatment Effect in High-Risk ALS

Chief of the Division of MS and Neuroimmunology at UConn Health.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]

A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD

, has been with the team since October 2019. Follow him on Twitter 

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]

Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

Using a Blood Collection Device to Advance Genetic Research in Parkinson Disease: James Beck, PhD & Ben Casavant, PhD

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Introduction to CMSC Best Practices in Multiple Sclerosis Therapies Roundtable 

Best Practices in Multiple Sclerosis

Best Practices in Multiple Sclerosis: Discussion

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis

Therapeutic Selection in Relapsing Multiple Sclerosis: Key Concepts

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis: Discussion

Therapeutic Selection for Progressive Multiple Sclerosis

Considerations in Therapeutic Selection for Progressive Multiple Sclerosis

Therapeutic Selection for Progressive Multiple Sclerosis: Discussion

Patients With Features of Aggressive Multiple Sclerosis or Poor Prognosis

Safety Concerns and Discussion: Highly Active Multiple Sclerosis

Therapeutic Goals of Treating Multiple Sclerosis 

Indicators of Suboptimal Therapies 

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis

Best Practices for Treating Pediatric Patients

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis: Discussion 

Best Practices for DMTs for Pregnant Patients With Multiple Sclerosis  

Multiple Sclerosis Drugs During Pregnancy 

Relapse Therapy and Postpartum Care for Pregnant Patients With Multiple Sclerosis 

Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis 

Discussion: Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis

Issues in Therapeutic Selection for Multiple Sclerosis 

Considerations When Selecting an Optimal DMT for Multiple Sclerosis Treatment 

Best Practices in Multiple Sclerosis Therapies: Future Perspectives

Expert Insights on the Best Practices of Multiple Sclerosis: Summary

Closing Thoughts: CMSC Best Practices in Multiple Sclerosis Therapies Roundtable

An expert-led panel discuss the best practices and different treatment considerations in multiple sclerosis.

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

CMSC Best Practices in Multiple Sclerosis Therapies Roundtable